Biotech Investing: How to Play Catalysts in the Drug Development Process

May 2, 2013

The volatility of biotech stocks provides an opportunity for investors. From discovery to commercialization, the drug development process takes many years. Different regulatory events and data from trials produces share price volatility. This creates an opportunity for investors. In this infographic, we outline all the regulatory events and what to watch for to make the most of biotech opportunities.

Spotlight

Cepheid

Over a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics with our first system and we’ve never looked back. And now, even with the largest installed base of any molecular platform, Cepheid is constantly innovating and evolving our capabilities. Our technology has been heralded as game-changing by healthcare leaders world-wide. We envision a better way for clinical institutions of any size, from small medical clinics to high-volume reference laboratories and major hospitals, to access the power of molecular diagnostics. Our GeneXpert® System delivers fast, scalable, and accurate diagnostic results while our expanding Xpert® test menu spans multiple clinical applications such as healthcare-associated infections, sexual health, critical infectious disease, virology, and oncology. Make a difference in healthcare and join us on this mission! For more details, please visit us at www.cepheid.com.

Other Infographics
news image

Building the European biotech sector with world-class science and innovation

Infographic | August 5, 2021

Europe continues to be a powerhouse of science and innovation. The region maintains a clear lead over China, the United States, and the rest of the world in terms of the quality and quantity of its science. For example, Europe is home to 43 of the global top 100 life-science universities, while the United States has 34. Europe is a powerhouse in scientific publishing as well, with roughly twice the output of the United States and three times that of China.Europe also leads in terms of quality, as measured by the number of citations for its publications. More than 40,000 biotech patents have been granted in Europe since 2015, although the region’s 3 percent CAGR in patent approvals between 2015 and 2019 lagged behind that of the United States (4 percent) and was a fraction of China’s (14 percent).Despite Europe’s strength in science and innovation, translation remains the biggest challenge. Translation of science into companies is stagnant. The distribution of newly funded biotechs remains unchanged across geographies over the last six years, and Europe accounts for only 25 percent of new biotechs. Future success will depend on improving the translation of research into new companies, raising more capital, and building entrepreneurial talent.

Read More
news image

What Paraspeckles Can Teach Us About Basic Cell Biology

Infographic | December 1, 2019

Discovering a new type of subnuclear body taught me how pursuing the unexpected can lead to new insights—in this case, about long noncoding RNAs and liquid-liquid phase separation in cells.

Read More
news image

Next-Gen Genetics: Cancer Therapies Create Investment Prospects

Infographic | August 12, 2022

The field (gene therapy) is not standing still, it’s evolving rapidly. If we have this discussion again in 18 months’ time, I don't know what we’ll be using then.

Read More
news image

Designing Genetic Circuit

Infographic | April 13, 2020

Near the turn of the millennium, James Collins and Stanislas Leibler independently undertook rather similar projects: design what would become synthetic biology’s seminal genetic circuits. And they came up with strikingly similar action plans—use E. coli to pair promoters with repressors that control one another’s behavior.

Read More
news image

Merck’s 23 CRISPR Patents Leading the way in genome-editing technology

Infographic | April 7, 2020

CRISPR Integration: CRISPR/Cas9 System for insertion in eukaryotic cells Compositions and use of CRISPR/Cas9 to integrate a new sequence of DNA after cutting genomic DNA. CRISPR-chrom: Improves access to the genome so that CRISPR-driven edits can be done more efficiently.

Read More
news image

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body

Infographic | April 16, 2020

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body. This infographic shows the events that occur following SARS-CoV-2 infection

Read More

Spotlight

Cepheid

Over a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics with our first system and we’ve never looked back. And now, even with the largest installed base of any molecular platform, Cepheid is constantly innovating and evolving our capabilities. Our technology has been heralded as game-changing by healthcare leaders world-wide. We envision a better way for clinical institutions of any size, from small medical clinics to high-volume reference laboratories and major hospitals, to access the power of molecular diagnostics. Our GeneXpert® System delivers fast, scalable, and accurate diagnostic results while our expanding Xpert® test menu spans multiple clinical applications such as healthcare-associated infections, sexual health, critical infectious disease, virology, and oncology. Make a difference in healthcare and join us on this mission! For more details, please visit us at www.cepheid.com.

Events